307 Westlake Avenue N
96 articles with Adaptive Biotechnologies
A recent report by the U.S. Bureau of Labor Statistics and CBRE Research identified Seattle—which happens to be the BioSpace Bio Forest Hotbed—as the fastest-growing life science market in the top 10 from 2014 to 2017, with a greater than 17-percent growth.
Adaptive Biotechnologies Announces Medicare Coverage of the clonoSEQ® Assay for MRD Testing in Patients with Multiple Myeloma and Acute Lymphoblastic Leukemia at Multiple Timepoints Throughout Treatment and Remission
Adaptive Biotechnologies announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) and leader in assessing diagnostic technologies through its MolDX program, has established coverage of the clonoSEQ® Assay for Medicare patients with multiple myeloma and B-cell acute lymphoblastic leukemia (ALL).
1/7/2019Seattle-based Adaptive Biotechnologies forged a collaboration with Genentech that could be worth up to $2 billion to develop and commercialize novel neoantigen directed T-cell therapies for the individualized treatment of a broad range of cancers.
Adaptive Biotechnologies to Enter into Worldwide Collaboration and License Agreement with Genentech to Develop Personalized Cellular Therapies for the Treatment of Cancer
Adaptive Biotechnologies, an immune-driven medicine company, today announced that it will enter into a worldwide collaboration and license agreement with Genentech,
Adaptive Biotechnologies and Collaborators to Present 28 Studies at ASH 2018 that Support the Use of the clonoSEQ® Assay to Detect and Monitor Minimal Residual Disease in Patients with Blood Cancers
New data demonstrate increasing use of MRD in multiple myeloma and acute lymphoblastic leukemia clinical trials to assess response to therapy
FDA Grants De Novo Designation for Adaptive Biotechnologies’ clonoSEQ Assay to Detect and Monitor Minimal Residual Disease (MRD) in Patients with Multiple Myeloma and Acute Lymphoblastic Leukemia
clonoSEQ is a first-in-class NGS assay and the first and only FDA-cleared MRD assay for any lymphoid cancer
A New Study Published in the Journal Blood Demonstrates that Measuring Minimal Residual Disease Negativity Using Adaptive Biotechnologies’ Next-Generation Sequencing Platform is a Major Predictive Indicator in Multiple Myeloma
Deep MRD Negativity was the Strongest Prognostic Factor of PFS Regardless of Treatment, Risk Factor and Disease Stage
Job hunting can be a challenging time for people. Finding open positions that fit your skill set and then competing with other highly-qualified people can be bruising, especially if you’re already a bit damaged from a recent layoff.
Rigel Pharmaceuticals, Inc. today announced that it has appointed Dean Schorno, CPA as Executive Vice President and Chief Financial Officer (CFO).
Adaptive Biotechnologies Announces a Collaboration with Sanofi to Use Adaptive’s clonoSEQ® Assay to Measure Minimal Residual Disease in Active and Future Isatuximab Multiple Myeloma Trials
Adaptive Biotechnologies announced today that it entered into an agreement with Sanofi to utilize Adaptive’s NGS-based clonoSEQ® Assay to assess minimal residual disease (MRD) status in response to isatuximab.
This new indication marks the first time the FDA has approved a therapy based on MRD status.
Adaptive Biotechnologies Appoints Veteran Molecular Diagnostics Executive Michael Pellini, MD, to Board of Directors
As the former CEO and current Chairman of the Board of Directors of Foundation Medicine, Dr. Pellini led the development and commercialization of a suite of molecular information products and services to aid in the diagnosis and management of advanced cancer, and to optimize the discovery and development of novel oncology therapies.
Adaptive Biotechnologies Announces Partnership with Microsoft to Decode the Human Immune System to Improve the Diagnosis of Disease
Adaptive Biotechnologies announced today their partnership with Microsoft to map the genetics of the human immune system, or immunome, in order to detect cancers and other diseases in their earliest stage, when they can be more effectively treated.
Adaptive Biotechnologies and Collaborators to Highlight Clinical Relevance of Measuring Residual Disease in Blood Cancers at ASH 2017
Data presented at ASH will demonstrate how Adaptive’s clonoSEQ Assay to measure MRD, the cancerous cells remaining in the body after treatment, can inform clinical care in patients with B and T cell lymphoid malignancies.
Adaptive Biotechnologies Announces a Collaboration with Amgen to Advance Clinical Development of the clonoSEQ Assay in Multiple Myeloma
Adaptive Biotechnologies announces it has entered into a collaboration agreement with Amgen to utilize Adaptive’s NGS-based clonoSEQ Assay in the Phase 3 CANDOR study.
Adaptive Biotech Expands Leadership To Bolster Integration Of Immune Profiling Into Clinical Care Setting
Adaptive Biotech Announces A Collaboration With Janssen Biotech To Use The clonoSEQ? Assay To Measure Minimal Residual Disease In Ongoing And Future DARZALEX? Multiple Myeloma Trials
Adaptive Biotech Announces A Collaboration With Janssen Biotech To Use The Clonoseq Assay To Measure Minimal Residual Disease In Ongoing And Future DARZALEX Multiple Myeloma Trials